



MARKET UPDATE: ACQUISITION OFFER BY BIOTON

Singapore and Australia. Friday 3 February, 2006. The SciGen Limited (ASX:SIE) board refers to an ASX announcement dated 2 February 2006 ("Announcement") made on behalf of Bioton S.A ("Bioton") regarding the lodgement on 1 February 2006 with ASIC of a prospectus ("Prospectus") which contains details of Bioton 's mandatory conditional offer to acquire all of the issued shares in SciGen ("Offer"). Bioton has indicated that the Offer document (Prospectus) is expected to be dispatched to SciGen shareholders whose addresses (recorded in the register of members) are in Singapore and Australia on 8 February 2006.

The SciGen board advises all SciGen share and CUFs holders that they take no action in relation to the Offer by Bioton at this stage. Pursuant to Singaporean legal requirements, the SciGen board will issue an Offeree Board Circular to SciGen share and CUFs holders on or around 22 February 2006 pursuant to which the independent directors will make a formal recommendation to you in relation to the Offer .

About SciGen

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong, and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

Further information:

Investor Relations and Media	Company
Fay Weston Buchan Consulting +61 2 9237 2800 +61 422 206 036 (mobile) fweston@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)